BioLineRx Ltd.

Stage 4 · Declining · week 8

As of Oct 22, 2026, BioLineRx is in Stage 4, the downtrend phase, now in week 8 (since Aug 28, 2026). It closed at $2.06, 45.5% below its 52-week high and below its 200-day average, which is falling.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. More about the company

$2.06

-2.37% today

$10.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BLRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 26w

S4 34w

S4 26w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 4w → S2 6w → S3 1w → S2 1w → S3 7w → S2 3w → S4 26w → S1 9w → S4 34w → S1 12w → S4 9w → S3 4w → S4 26w → S1 7w → S2 4w → S3 3w → S4 8w current

Total tracked: 166 weeks across 18 stage runs.

BLRX among Biotechnology332nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…332	BLRXBioLineRx Ltd.	Stage 4 · wk 8	26	−19.5%

vs 52W High

-45.5%

$1.98 lo$3.78 hi

45.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 8

1w13w26w

Week 8, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-25.5%

200 DMA: $2.77 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.26x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.5%

-27.0%

-10.4%

YTD

-26.4%

-43.6%

Scan Membership

Breakout Watch

Latest: 2024-01-04

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 8 · Vol 0.26x

2026-10-21S4

Wk 8 · Vol 0.09x

2026-10-20S4

Wk 8 · Vol 0.15x

2026-10-19S4

Wk 8 · Vol 1.77x

2026-10-16S4

Wk 7 · Vol 0.64x

2026-10-15S4

Wk 7 · Vol 1.51x

2026-10-14S4

Wk 7 · Vol 1.25x

2026-10-13S4

Wk 7 · Vol 0.63x

2026-10-12S4

Wk 7 · Vol 1.55x

2026-10-09S4

Wk 6 · Vol 0.53x

2026-10-08S4

Wk 6 · Vol 1.03x

2026-10-07S4

Wk 6 · Vol 1.35x

Moving averages & range

50 DMA

$2.49

200 DMA

$2.77

52W High

$3.78

52W Low

$1.98

5D Low

$1.98

Resistance levels (recent highs)

20d High

$2.60

60d High

$3.00

120d High

$3.78

250d High

$3.78

Next resistance

+26.2%

to 20d High

ROE

-55.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

BioLineRx: quick answers

What stage is BioLineRx in?

As of Oct 22, 2026, BioLineRx (BLRX) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 28, 2026 and is in week 8. What the four stages mean

Is BioLineRx in an uptrend?

No. BioLineRx is in a Stage 4 downtrend. It trades 25.5% below its 200-day average, which is falling.

How far is BioLineRx from its 52-week high?

BioLineRx closed at $2.06 on Oct 22, 2026, 45.5% below its 52-week high of $3.78. Its 52-week low is $1.98.

How has BioLineRx performed over the past year?

As of Oct 22, 2026, BioLineRx is down 43.6% over the past year and down 26.4% so far in 2026.

Which sector and industry is BioLineRx in?

BioLineRx is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.